The combination of either ivosidenib or enasidenib with induction/consolidation chemotherapy in newly diagnosed IDH1/2-mutated AML has been studied in a phase 1 trial that showed induction CR rates of 55% for ivosidenib and 47% for enasidenib [90]. The gene discussed is IDH1; the disease is acute myeloid leukemia.